{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:15Z","timestamp":1793727855145,"version":"4.6.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1038\/s41375-024-02290-y","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:02:14Z","timestamp":1717416134000},"page":"1621-1625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CD8+ CD28\u2212 regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study"],"prefix":"10.1038","volume":"38","author":[{"given":"Katharina","family":"Kriegsmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gigi Nu Hoang Quy","family":"Ton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-7199","authenticated-orcid":false,"given":"Mohamed H. S.","family":"Awwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Fenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Munder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00fcrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor W.","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-3234","authenticated-orcid":false,"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-5491","authenticated-orcid":false,"given":"Roland","family":"Schroers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"von Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Schieferdecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Thomalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Mahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6082-7710","authenticated-orcid":false,"given":"Ullrich","family":"Graeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Hensel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Seidel-Gl\u00e4tzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7803-0814","authenticated-orcid":false,"given":"Hans J.","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-1252","authenticated-orcid":false,"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5596-2405","authenticated-orcid":false,"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"2290_CR1","doi-asserted-by":"publisher","first-page":"13009","DOI":"10.1073\/pnas.202491499","volume":"99","author":"MV Dhodapkar","year":"2002","unstructured":"Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA. 2002;99:13009\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2290_CR2","doi-asserted-by":"publisher","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","volume":"7","author":"KR Muthu Raja","year":"2012","unstructured":"Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PloS One. 2012;7:e47077.","journal-title":"PloS One"},{"key":"2290_CR3","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","volume":"62","author":"SM Collins","year":"2013","unstructured":"Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol, Immunother. 2013;62:1841\u20139.","journal-title":"Cancer Immunol, Immunother"},{"key":"2290_CR4","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/2326-6066.CIR-18-0579","volume":"7","author":"T Pazina","year":"2019","unstructured":"Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, et al. Enhanced SLAMF7 homotypic interactions by elotuzumab improves NKcell killing of multiple myeloma. Cancer Immunol Res. 2019;7:1633\u201346.","journal-title":"Cancer Immunol Res"},{"key":"2290_CR5","doi-asserted-by":"crossref","unstructured":"MHS Awwad, A Mahmoud, H Bruns, H Echchannaoui, K Kriegsmann, R Lutz et al. Selective elimination of immunosuppressive T cells in patients with multiple myeloma. Leukemia. 2021;35:2602\u20132615.","DOI":"10.1038\/s41375-021-01172-x"},{"key":"2290_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/blood-2021-147323","volume":"138","author":"H Goldschmidt","year":"2021","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Besemer B, H\u00e4nel M, Miah K, et al. Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: results from the randomized phase III GMMG-HD6 Trial. Blood. 2021;138:486.","journal-title":"Blood"},{"key":"2290_CR7","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","volume":"8","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021;8:e45\u201354.","journal-title":"Lancet Haematol"},{"key":"2290_CR8","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","volume":"9","author":"MA Dimopoulos","year":"2022","unstructured":"Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksa\u00e7 M, et al. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022;9:e403\u201314.","journal-title":"Lancet Haematol"},{"key":"2290_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","volume":"178","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, et al. Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178:896\u2013905.","journal-title":"Br J Haematol"},{"key":"2290_CR10","doi-asserted-by":"publisher","first-page":"8040","DOI":"10.1200\/JCO.2018.36.15_suppl.8040","volume":"36","author":"S Lonial","year":"2018","unstructured":"Lonial S, Dimopoulos MA, Weisel K, White D, Moreau P, Mateos M-V, et al. Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide\/dexamethasone (ELd) vs Ld in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2018;36:8040.","journal-title":"J Clin Oncol"},{"key":"2290_CR11","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood.2021013290","volume":"139","author":"MR Gaballa","year":"2022","unstructured":"Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, et al. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022;139:1908\u201319.","journal-title":"Blood"},{"key":"2290_CR12","doi-asserted-by":"crossref","unstructured":"MV Dietz, KLA Quintelier, JP van Kooten, NL de Boer, M Vink, ARM Brandt-Kerkhof et al. Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial. J Immunother Cancer. 2023;11:e007070.","DOI":"10.1136\/jitc-2023-007070"},{"key":"2290_CR13","doi-asserted-by":"publisher","first-page":"eabi9591","DOI":"10.1126\/science.abi9591","volume":"376","author":"J Li","year":"2022","unstructured":"Li J, Zaslavsky M, Su Y, Guo J, Sikora MJ, Van Unen V, et al. KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19. Sci (NY). 2022;376:eabi9591.","journal-title":"Sci (NY)"},{"key":"2290_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/eji.201948362","volume":"50","author":"L Pangrazzi","year":"2020","unstructured":"Pangrazzi L, Reidla J, Carmona Arana JA, Naismith E, Miggitsch C, Meryk A, et al. CD28 and CD57 define four populations with distinct phenotypic properties within human CD8+ T cells. Eur J Immunol. 2020;50:363\u201379.","journal-title":"Eur J Immunol"},{"key":"2290_CR15","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00262-018-2230-0","volume":"67","author":"J Plaumann","year":"2018","unstructured":"Plaumann J, Engelhardt M, Awwad MHS, Echchannaoui H, Amman E, Raab MS, et al. IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells. Cancer Immunol Immunother. 2018;67:1695\u2013707.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02290-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02290-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02290-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T23:11:14Z","timestamp":1719875474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02290-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2290"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02290-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Katharina Kriegsmann: None. Gigi Nu Hoang Quy Ton: None. Mohamed H. S. Awwad: None. Axel Benner: None. Uta Bertsch: None. Britta Besemer: Honoraria Janssen Cilag, Sanofi, GSK. Mathias H\u00e4nel: Honoraria Novartis, SOBI, Gilead Sciences, Falk Foundation Consulting or Advisory Role Novartis, BMS\/Celgene, Gilead Sciences, Pfizer, Incyte, Sanofi\/Aventis, Roche, Amgen, SOBI, Janssen. Roland Fenk: Honoraria Amgen, BMS, GSK, Janssen, Sanofi, Takeda Travel grants BMS, Janssen, Sanofi. Markus Munder: Honoraria Janssen Oncology, BMS GmbH & Co KG, GlaxoSmithKline, Sanofi Consulting or Advisory Role Janssen Oncology, BMS GmbH & Co KG, GlaxoSmithKline, Sanofi, Takeda, Amgen, Stemline Therapeutics Travel, Accommodations, Expenses Amgen, Bristol Myers Squibb. Jan D\u00fcrig: Advisory Board Bristol-Myers Squibb, Celgene, Janssen Speakers bureau Celgene, Janssen. Igor W. Blau: None. Stefanie Huhn: None. Dirk Hose: None. Anna Jauch: None. Christoph Mann: Consulting or Advisory Role Sanofi, BMS, Janssen. Niels Weinhold: None. Christof Scheid: None. Roland Schroers: None. Ivana von Metzler: Honoraria Pfizer, Sanofi, BMS, GSK, Amgen, Janssen, Takeda, and AstraZeneca Consulting and Advisory Role Oncopeptides. Aneta Schieferdecker: None. J\u00f6rg Thomalla: None. Peter Reimer: Bristol Myers Squibb was one of several sponsors of continuing education at our clinic. Rolf Mahlberg: None. Ullrich Graeven: Stock and Other Ownership Interests Biontech Honoraria Boehringer Ingelheim Amgen, AstraZeneca, Bristol-Myers Squibb, MSD Oncology, Sanofi Aventis GmbH, Fujifilm, Novartis, Cellrion, Ipsen Consulting or Advisory Role Amgen, MSD Oncology Research Funding Ipsen, Macrogenics Travel, Accommodations, Expenses Boehringer Ingelheim GSK. Stephan Kremers: None. Uwe Martens: Consulting or Advisory Role Celgene, Sanofi-Aventis GmbH. Christian Kunz: Advisory Boards Amgen, BMS, Incyte, Roche, Novartis, Abbvie Travel, Accommodations, Expenses Beigene, Sanofi, Abbvie, BMS, Lilly. Manfred Hensel: None. Andrea Seidel-Gl\u00e4tzer: None. Katja C. Weisel: Honoraria Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, BMS, BeiGene, Janssen, GSK, Karyopharm, Nobartis, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Stemline, Takeda, Menarini Research grant Abbvie, Amgen, BMS, Janssen, GSK, Sanofi, Takeda Consulting or Advisory Role Abbvie, Amgen, Adaptive Biotech, BMS, BeiGene, Janssen, GSK, Karyopharm, Oncopeptides, Pfizer, Roche Pharma, Sanofi, Takeda, Menarini. Hans J. Salwender: Honoraria AbbVie, Amgen, AstraZeneca, BMS\/Celgene, Genzyme, GSK, Janssen, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, Takeda Travel Accommodations and Expenses Amgen, BMS\/Celgene, Janssen, Sanofi. Carsten M\u00fcller-Tidow: None. Marc S. Raab: Consulting or Advisory Role BMS, Amgen, GSK, Janssen, Sanofi, Pfizer, AbbVie, Takeda Research Funding BMS, Janssen, Sanofi, Heidelberg Pharma Travel, Accomodations, Expenses BMS, Amgen, Janssen Honoraria BMS, Janssen, AbbVie, Sanofi. Hartmut Goldschmidt: Grants and\/or provision of Investigational Medicinal Product Amgen, Array Biopharma\/Pfizer, BMS\/Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns. Hopkins University, Mundipharma GmbH, Sanofi Research Funding Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte Corporation, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme (MSD), MorphoSys AG, Pfizer, Sanofi, Takeda, Novartis Advisory Boards Amgen, BMS, Janssen, Sanofi, Adaptive Biotechnology Honoraria Amgen, BMS, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Travel Accomodations, Expenses Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Elias K. Mai: Consulting or Advisory Role Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi Aventis, Stemline, Takeda; Honoraria Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi Aventis, Stemline, Takeda Research Funding Sanofi Aventis Travel Accommodations and Expenses Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi Aventis, Stemline, Takeda. Michael Hundemer: Consulting or Advisory Role Beigene, Becton Dickinson Research Funding Novartis, BeiGene, Sanofi Travel, Accomodations, Expenses BeiGene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}